Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,154
Out of 4,884 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $41.74 | +0.62% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $196.82 | +90.53% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $73.30 | +56.89% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $87.78 | +4.81% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $15.30 | -21.57% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $11.25 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $43.54 | +106.71% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $237.55 | +13.66% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $103.50 | -34.30% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $12.35 | +264.37% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $119.90 | +129.36% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $17.86 | +107.17% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $82.93 | -27.65% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $104.32 | -66.45% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $301.05 | -73.09% | 2 | Feb 22, 2018 | |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $41.74
Upside: +0.62%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $196.82
Upside: +90.53%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $73.30
Upside: +56.89%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $87.78
Upside: +4.81%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $15.30
Upside: -21.57%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $11.25
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $43.54
Upside: +106.71%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $237.55
Upside: +13.66%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $103.50
Upside: -34.30%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $12.35
Upside: +264.37%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $119.90
Upside: +129.36%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $17.86
Upside: +107.17%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $82.93
Upside: -27.65%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $104.32
Upside: -66.45%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $301.05
Upside: -73.09%